<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01610102</url>
  </required_header>
  <id_info>
    <org_study_id>C1104</org_study_id>
    <nct_id>NCT01610102</nct_id>
  </id_info>
  <brief_title>PROGRESS-AMS 1.0 Clinical Long Term Follow-Up</brief_title>
  <official_title>Clinical Performance and Angiographic Results of Coronary Stenting With Absorbable Metal Stents, Clinical Long Term Follow-Up</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotronik AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biotronik AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to collect long term clinical follow-up data on all
      patients enrolled in the PROGRESS AMS-1.0 study to assess long term safety of the AMS-1.0
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The first clinical experience with AMS was in infrapopliteal arteries and demonstrated safety
      and acceptable patency rates up to 12 months post implantation. These encouraging results led
      to the initiation of the first trial to treat human coronary lesions with AMS named Clinical
      Performance and angiographic Results of Coronary Stenting with Absorbable Metal Stents
      (PROGRESS AMS-1). Although an ischemic driven target lesion revascularization rate of 26.7%
      (16/60) was observed during the PROGRESS AMS-1 study, it demonstrated that biodegradable
      magnesium stents can be implanted safely in coronary arteries, and the stents degraded as
      intended without causing stent thrombosis, myocardial infarction or death at one year. No
      adverse device effects from the absorbable nature of the stents or its constituents were
      detected. The continued clinical follow-up and retrospective evaluation of all angiographies
      and IVUS films on all eligible patients enrolled in the PROGRESS-AMS 1.0 will give important
      information on the long term safety of absorbable metal scaffolds and thus can support
      improvement of the device.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Target Lesion Failure (TLF)</measure>
    <time_frame>up to 7 years follow-up</time_frame>
    <description>Composite of cardiac death, target vessel myocardial infarction, clinically driven target lesion revascularization</description>
  </primary_outcome>
  <enrollment type="Actual">55</enrollment>
  <condition>Long Term Safety of the AMS 1.0</condition>
  <eligibility>
    <study_pop>
      <textblock>
        63 eligible patints previously enrolled in the PROGRESS AMS-1 study
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent form available prior to clinical long term follow-up

        Exclusion Criteria:

          -  Patent did not sign the informed consent form prior to clinical long term follow-up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raimund Erbel, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Westdeutsches Herzzentrum Essen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Esther Gerteis</last_name>
    <role>Study Director</role>
    <affiliation>Biotronik AG</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Austin &amp; Repatriation Medical Centre</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>O.L.V. Ziekenhuis Aalst</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westdeutsches Herzzentrum Essen</name>
      <address>
        <city>Essen</city>
        <state>NRW</state>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catharina Zieckenhuis</name>
      <address>
        <city>Eindhoven</city>
        <zip>5623</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Luzerner Kantonsspital</name>
      <address>
        <city>Luzern</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Zürich</name>
      <address>
        <city>Zürich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Switzerland</country>
  </location_countries>
  <removed_countries>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2012</study_first_submitted>
  <study_first_submitted_qc>May 31, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2012</study_first_posted>
  <last_update_submitted>February 4, 2015</last_update_submitted>
  <last_update_submitted_qc>February 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>clinical follow-up</keyword>
  <keyword>up to 7 years</keyword>
  <keyword>all patients enrolled in the main study</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

